Feron Olivier
University of Louvain Medical School, Unit of Pharmacology and Therapeutics, UCL-FATH 5349, 53 Avenue E. Mounier, B-1200 Brussels, Belgium.
Trends Pharmacol Sci. 2004 Oct;25(10):536-42. doi: 10.1016/j.tips.2004.08.008.
The fact that a single blood vessel can support the life of thousands of tumor cells has been known for a long time. However, therapeutic strategies that aim to impair vascular development in tumors are only slowly emerging in the clinics. Nevertheless, the accumulation of data from many successful preclinical studies of the effects of a variety of drugs that target tumor vasculature provides clues that should help rationalize future treatment modalities for human tumors. Indeed, the 'old' view of an immature and non-functional vascular network within tumors has evolved and, in this article, we will show that the concept of tumor heterogeneity should be extended to the vascular compartment. In addition, we will review recent data documenting that both mature and immature vessels coexist within tumors and, importantly, that their relative density responds to a dynamic process that evolves with time and treatments.
单个血管能够维持数千个肿瘤细胞生命这一事实早已为人所知。然而,旨在破坏肿瘤血管生成的治疗策略在临床上才刚刚开始缓慢出现。尽管如此,许多针对肿瘤脉管系统的药物进行的成功临床前研究积累的数据提供了线索,有助于合理规划未来人类肿瘤的治疗方式。事实上,肿瘤内血管网络不成熟且无功能这一“旧”观点已经有所发展,在本文中,我们将表明肿瘤异质性的概念应扩展到血管部分。此外,我们将回顾最近的数据,这些数据表明成熟血管和不成熟血管在肿瘤内共存,重要的是,它们的相对密度对一个随时间和治疗而演变的动态过程有反应。